ITM-10X

ITM-10X is a preclinical-stage radiopharmaceutical candidate being developed by Isotope Technologies Munich (ITM), formerly known as Isotope Technologies Garching, for the treatment of various oncology indications. The designation ITM-10X serves as a placeholder for an undisclosed asset within the company's early-stage pipeline where specific details regarding the molecular target and the radioisotope (such as Lutetium-177, Actinium-225, or Terbium-161) have not yet been publicly identified. Like other candidates in ITM's portfolio, this drug is designed as a targeted radionuclide therapy, utilizing a specific targeting vector (such as a peptide or antibody) to deliver ionizing radiation directly to tumor-associated antigens, thereby inducing DNA damage and cell death in malignant tissues while sparing healthy cells.